• James Ayodele Ogunmodede, Adebusola Jane Ogunmodede, Bolade Folasade Dele-Ojo, Idris Abiola Yusuf, Adeseye Abiodun Akintunde, Oladimeji Akeem Bolarinwa, Taiye Peter Omojasola, Ibraheem Adeola Katibi, and Ayodele Babatunde Omotoso.
• Department of Medicine, University of Ilorin, Ilorin, Kwara state, Nigeria.
• Afr Health Sci. 2022 Dec 1; 22 (4): 505518505-518.

BackgroundSeveral observational reports from different parts of the world have shown that systemic hypertension (hypertension) was the single commonest comorbid condition in hospitalized COVID-19 patients. Hypertension is also the most prevalent comorbidity reported among patients who developed severe disease, were admitted to Intensive Care Unit, needed mechanical ventilatory support, or who died on admission. The objective of this systematic review is to study the association between hypertension and specific clinical outcomes of COVID-19 disease which are- development of severe COVID-19 disease, need for admission in the intensive care unit (ICU) or critical care unit (CCU), need for mechanical ventilation or death.MethodsWe searched the PubMed, SCOPUS, and Google Scholar databases up till June 28, 2020 for original research articles that documented the risk factors of mortality in patients with COVID-19 using the PRISMA guideline.ResultsOne hundred and eighty-two articles were identified using pre-specified search criteria, of which 33 met the study inclusion criteria. Only three were prospective studies. Most studies documented hypertension as the most prevalent comorbidity. The association of hypertension with development of severe COVID-19 disease was not conclusive, majority of studies however found an associated with mortality.ConclusionHypertension affects the clinical course and outcome of COVID-19 disease in many cohorts. Prospective studies are needed to further understand this relationship.© 2022 Ogunmodede JA et al.

14 keywords...

hide…